Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 6105691, 11 pages
https://doi.org/10.1155/2018/6105691
Research Article

Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters

1Laboratório de Hematologia, Genética e Biologia Computacional (LHGB), Fiocruz Bahia-Instituto Gonçalo Moniz (IGM), Rua Waldemar Falcão 121, Candeal, 40296-710 Salvador, BA, Brazil
2Laboratório de Pesquisa em Anemia (LPA), Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal da Bahia, Rua Barão do Jeremoabo 147, Ondina, 40170-115 Salvador, BA, Brazil

Correspondence should be addressed to Marilda de Souza Gonçalves; rb.zurcoif.aihab@iram

Received 12 August 2017; Revised 25 November 2017; Accepted 4 December 2017; Published 28 January 2018

Academic Editor: Fabrizia Bamonti

Copyright © 2018 Sètondji Cocou Modeste Alexandre Yahouédéhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Rees, T. N. Williams, and M. T. Gladwin, “Sickle-cell disease,” The Lancet, vol. 376, no. 9757, pp. 2018–2031, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Goncalves, “Comment on “Molecular analysis and association with clinical and laboratory manifestations in children with sickle cell anemia”,” Revista Brasileira de Hematologia e Hemoterapia, vol. 36, no. 5, pp. 315–318, 2014. View at Publisher · View at Google Scholar
  3. M. R. Laurentino, P. A. M. Filho, M. C. Barbosa, I. C. J. Bandeira, L. B. da Silva Rocha, and R. P. Gonçalves, “Influence of βS-globin haplotypes hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia,” Revista Brasileira de Hematologia e Hemoterapia, vol. 36, no. 2, pp. 121–125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. Q. Ma, D. F. Wyszynski, J. J. Farrell et al., “Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea,” The Pharmacogenomics Journal, vol. 7, no. 6, pp. 386–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. O. Folashade and E. H. Omoregie, “Chemical constituents and biological activity of medicinal plants used for the management of sickle cell disease-a review,” Journal of Medicinal Plants Research, vol. 7, no. 48, pp. 3452–3476, 2013. View at Google Scholar
  6. S. Laurance, F.-X. Pellay, O. P. Dossou-Yovo et al., “Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease,” Pharmacogenetics and Genomics, vol. 20, no. 4, pp. 257–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. A. Nottage, J. S. Hankins, M. Smeltzer et al., “Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program,” PLoS One, vol. 8, no. 8, article e72077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. A. C. Silva-Pinto, I. L. Angulo, D. M. Brunetta et al., “Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil,” São Paulo Medical Journal, vol. 131, no. 4, pp. 238–243, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. E. Ware, “How I use hydroxyurea to treat young patients with sickle cell anemia,” Blood, vol. 115, no. 26, pp. 5300–5311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. E. Ware, B. Eggleston, R. Redding-Lallinger et al., “Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy,” Blood, vol. 99, no. 1, pp. 10–14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Andrae, “Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea,” Biochemical and Biophysical Research Communications, vol. 118, no. 2, pp. 409–415, 1984. View at Publisher · View at Google Scholar · View at Scopus
  12. S. B. King, “The nitric oxide producing reactions of hydroxyurea,” Current Medicinal Chemistry, vol. 10, no. 6, pp. 437–452, 2003. View at Publisher · View at Google Scholar
  13. M. T. Gladwin, J. H. Shelhamer, F. P. Ognibene et al., “Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease,” British Journal of Haematology, vol. 116, no. 2, pp. 436–444, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. B. King, “N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors,” Current Topics in Medicinal Chemistry, vol. 5, no. 7, pp. 665–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. W. Bock, “Homeostatic control of xeno- and endobiotics in the drug-metabolizing enzyme system,” Biochemical Pharmacology, vol. 90, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Božina, V. Bradamante, and M. Lovrić, “Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk,” Archives of Industrial Hygiene and Toxicology, vol. 60, no. 2, pp. 217–242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Zupa, A. Sgambato, G. Bianchino et al., “GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: a case-control study,” Anticancer Research, vol. 29, no. 5, pp. 1709–1714, 2009. View at Google Scholar
  18. O. Bushueva, M. Solodilova, V. Ivanov, and A. Polonikov, “Gender-specific protective effect of the −463G>A polymorphism of myeloperoxidase gene against the risk of essential hypertension in Russians,” Journal of the American Society of Hypertension, vol. 9, no. 11, pp. 902–906, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ergen, H. Karagedik, Z. E. Karaali, and T. Isbir, “An association between MPO -463G/A polymorphism and type 2 diabetes,” Folia Biol Praha, vol. 60, no. 3, pp. 108–112, 2014. View at Google Scholar
  20. F. Bruge, S. Virgili, T. Cacciamani, F. Principi, L. Tiano, and G. P. Littarru, “NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt’s lymphoma cell lines,” BioFactors, vol. 32, no. 1–4, pp. 71–81, 2008. View at Publisher · View at Google Scholar
  21. G. J. Morgan and M. T. Smith, “Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults,” American Journal of PharmacoGenomics, vol. 2, no. 2, pp. 79–92, 2002. View at Publisher · View at Google Scholar
  22. T. S. Balmukhanov, A. K. Khanseitova, V. G. Nigmatova, E. E. Ashirbekov, S. Z. Talaeva, and N. A. Aitkhozhina, “Polymorphisms at GSTM1, GSTP1, GSTT1 detoxification genes loci and risk of breast cancer in Kazakhstan population,” Advances in Breast Cancer Research, vol. 02, no. 04, pp. 114–118, 2013. View at Publisher · View at Google Scholar
  23. W. A. García-Suástegui, L. A. Ramos-Chávez, M. Rubio-Osornio et al., “The role of CYP2E1 in the drug metabolism or bioactivation in the brain,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 4680732, 14 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. Y.-J. Sheng, G. Wu, H.-Y. He et al., “The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis,” Infection, Genetics and Evolution, vol. 24, pp. 34–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Nikpoor, G. Turecki, C. Fournier, P. Théroux, and G. A. Rouleau, “A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians,” American Heart Journal, vol. 142, no. 2, pp. 336–339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Lozić, D. Primorac, R. Glavinić, R. K. Samija, and T. Zemunik, “Analysis of the C609T polymorphism of NQO1 gene in South Croatian patients with hematological malignancies,” Collegium Antropologicum, vol. 35, no. 2, pp. 385–388, 2011. View at Google Scholar
  27. X.-L. Su, M.-R. Yan, L. Yang, and Qimuge-Suyila, “NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia,” Chinese Journal of Cancer Research, vol. 24, no. 4, pp. 317–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Zaker, A. Safaei, N. Nasiri, M. Abdollahzadeh, and V. Pazhakh, “The association of NAD(P)H:quinine oxidoreductase gene polymorphisms with pediatric acute lymphoblastic leukemia,” Laboratory Medicine, vol. 43, no. 6, pp. 256–261, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. M. Kelly, J. P. Perentesis, and Children’s Oncology Group (COG), “Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin’s lymphoma at risk of treatment-related complications,” Annals of Oncology, vol. 13, Supplement 1, pp. 34–39, 2002. View at Publisher · View at Google Scholar
  30. C.-M. Gao, T. Takezaki, W. J-Z et al., “CYP2E1 Rsa I polymorphism impacts on risk of colorectal cancer association with smoking and alcohol drinking,” World Journal of Gastroenterology, vol. 13, no. 43, pp. 5725–5730, 2007. View at Publisher · View at Google Scholar
  31. N. Dunna, C. Anuradha, S. Vure et al., “NQO12 [NAD (P) H: quinone oxidoreductase 1] polymorphism and its influence on acute leukemia risk,” Biology and Medicine, vol. 3, no. 3, pp. 19–25, 2011. View at Google Scholar
  32. M. Sutton, E. E. Bouhassira, and R. L. Nagel, “Polymerase chain reaction amplification applied to the determination of β-like globin gene cluster haplotypes,” American Journal of Hematology, vol. 32, no. 1, pp. 66–69, 1989. View at Publisher · View at Google Scholar · View at Scopus
  33. S. S. Chong, C. D. Boehm, D. R. Higgs, and G. R. Cutting, “Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia,” Blood, vol. 95, no. 1, pp. 360–362, 2000. View at Google Scholar
  34. F. R. Pallis, N. Conran, K. Y. Fertrin, S. T. Olalla Saad, F. F. Costa, and C. F. Franco-Penteado, “Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients,” British Journal of Haematology, vol. 164, no. 2, pp. 286–295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Zorca, L. Freeman, M. Hildesheim et al., “Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension,” British Journal of Haematology, vol. 149, no. 3, pp. 436–445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. M. Aleluia, C. C. da Guarda, R. P. Santiago et al., “Association of classical markers and establishment of the dyslipidemic sub-phenotype of sickle cell anemia,” Lipids in Health and Disease, vol. 16, no. 1, pp. 74–79, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Dehury, P. Purohit, S. Patel et al., “Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1-5(G→C) mutation,” Pediatric Blood & Cancer, vol. 62, no. 6, pp. 1017–1023, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. D. K. Shome, A. Al Ajmi, A. A. Radhi, E. J. Mansoor, and K. S. Majed, “The effect of hydroxyurea therapy in Bahraini sickle cell disease patients,” Indian J Hematol Blood Transfus, vol. 32, no. 1, pp. 104–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. M. R. Laurentino, T. M. de Jesus Ponte Carvalho, T. E. de Jesus dos Santos, M. C. Barbosa, T. N. dos Santos, and R. P. Gonçalves, “Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy,” Jornal Brasileiro de Patologia e Medicina Laboratorial, vol. 50, no. 3, pp. 184–188, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. L. de Souza Torres, D. G. H. da Silva, E. B. Junior et al., “The influence of hydroxyurea on oxidative stress in sickle cell anemia,” Revista Brasileira de Hematologia e Hemoterapia, vol. 34, no. 6, pp. 421–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Feld, G. J. Kato, C. Koh et al., “Liver injury is associated with mortality in sickle cell disease,” Alimentary Pharmacology and Therapeutics, vol. 42, no. 7, pp. 912–921, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Kouegnigan Rerambiah, L. Essola Rerambiah, A. Mbourou Etomba et al., “Blood transfusion, serum ferritin, and iron in hemodialysis patients in Africa,” Journal of Blood Transfusion, vol. 2015, Article ID 720389, 5 pages, 2015. View at Publisher · View at Google Scholar
  43. S. Krishnan, Y. Setty, S. G. Betal et al., “Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises,” British Journal of Haematology, vol. 148, no. 5, pp. 797–804, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. Z.-T. Shen, W. X-H, B. Li et al., “CYP2E1 Rsa I/Pst I polymorphism and lung cancer susceptibility: a meta-analysis involving 10,947 subjects,” Journal of Cellular and Molecular Medicine, vol. 19, no. 9, pp. 2136–2142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Nomani, L. Hagh-Nazari, A. Aidy et al., “Association between GSTM1, GSTT1, and GSTP1 variants and the risk of end stage renal disease,” Renal Failure, vol. 38, no. 9, pp. 1455–1461, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. F.-F. Han, C.-L. Guo, L.-L. Gong, Z. Jin, and L.-H. Liu, “Effects of the NQO1 609C>T polymorphism on leukemia susceptibility: evidence from a meta-analysis,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 9, pp. 5311–5316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. X.-E. Peng, Y.-Y. Jiang, X.-S. Shi, and Z.-J. Hu, “NQO1 609C > T polymorphism interaction with tobacco smoking and alcohol drinking increases colorectal cancer risk in a Chinese population,” Gene, vol. 521, no. 1, pp. 105–110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H. M. Hassan, H. Guo, B. A. Yousef et al., “Role of inflammatory and oxidative stress, cytochrome P450 2E1, and bile acid disturbance in rat liver injury induced by isoniazid and lipopolysaccharide cotreatment,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 9, pp. 5285–5293, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. Y.-F. Piao, J.-T. Li, and Y. Shi, “Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver,” World Journal of Gastroenterology, vol. 9, no. 11, pp. 2612–2615, 2003. View at Publisher · View at Google Scholar
  51. N. Maicas, J. van der Vlag, J. Bublitz et al., “Human alpha-1-antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury,” PLoS One, vol. 12, no. 2, article e0168981, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Nunobiki, M. Ueda, H. Akise et al., “GSTM1, GSTT1, and NQO1 polymorphisms in cervical carcinogenesis,” Human Cell, vol. 28, no. 3, pp. 109–113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Muslu, Z. N. Dogruer, G. Eskandari, A. Atici, S. Kul, and U. Atik, “Are glutathione S-transferase gene polymorphisms linked to neonatal jaundice?” European Journal of Pediatrics, vol. 167, no. 1, pp. 57–61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. E. C. Ebert, M. Nagar, and K. D. Hagspiel, “Gastrointestinal and hepatic complications of sickle cell disease,” Clinical Gastroenterology and Hepatology, vol. 8, no. 6, pp. 483–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. K. Ballas, “Lactate dehydrogenase and hemolysis in sickle cell disease,” Blood, vol. 121, no. 1, pp. 243-244, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. E. A. G. Abdel Ghany, N. F. Hussain, and S. K. A. Botros, “Glutathione S-transferase gene polymorphisms in neonatal hyperbilirubinemia,” Journal of Investigative Medicine, vol. 60, no. 1, pp. 18–22, 2012. View at Publisher · View at Google Scholar